Wednesday, November 11, 2026

NVIDIA Releases Five Open-Source AI Model Families Spanning Robotics, Biology, and Autonomous Systems

NVIDIA launched multiple open-source AI models at GTC 2026, including Cosmos 3 for world simulation, Isaac GR00T robotics models, Nemotron 3 language models, and Proteina-Complexa for protein design. The release extends beyond language models into physical AI and scientific discovery, with partnerships across Adobe, LangChain, and CrowdStrike.

LM Salvado

March 21, 2026

NVIDIA Releases Five Open-Source AI Model Families Spanning Robotics, Biology, and Autonomous Systems
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

NVIDIA unveiled five open-source AI model families at GTC 2026, marking an expansion from language processing into robotics, autonomous systems, and scientific research.1

The release includes Cosmos 3, a world foundation model for simulation; Isaac GR00T N1.7 and N2 for robotics applications; Nemotron 3 language models; Alpamayo 1.5; and Proteina-Complexa for protein design.2 The models target developers building intelligent agents across digital and physical industries.

"Open source AI has become a global force for innovation," said Kari Briski, NVIDIA's vice president of product management.3 "From biology and scientific discovery to robotics and autonomous machines, NVIDIA open model families extend intelligence beyond language, enabling developers worldwide to build intelligent agents and power breakthroughs across digital and physical industries."3

The Isaac GR00T models address physical AI applications, allowing robots to learn from visual demonstrations and adapt to real-world environments. Cosmos 3 provides world simulation capabilities for training autonomous systems without requiring extensive real-world data collection.

Proteina-Complexa targets drug discovery and biological research, generating protein structures for therapeutic development. The model joins NVIDIA's scientific AI portfolio alongside Alpamayo 1.5.

NVIDIA partnered with Adobe, LangChain, and CrowdStrike to accelerate enterprise adoption.4 The partnerships aim to integrate the models into existing development workflows and cybersecurity systems.

The release shifts NVIDIA's open-source strategy beyond its established position in language models. Physical AI and scientific discovery models address compute-intensive applications where NVIDIA's GPU infrastructure provides advantages over CPU-based alternatives.

Developers can access the models through NVIDIA's AI platform, with pre-trained weights and training frameworks available for customization. The company provides reference implementations for common use cases in robotics, autonomous vehicles, and laboratory automation.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· March 16, 2026
    NVIDIA Expands Open Model Families to Power the Next Wave of Agentic, Physical and Healthcare AI
  2. [2]News articleYahoo Finance· March 16, 2026
    Adobe and NVIDIA Announce Strategic Partnership to Deliver the Next Generation of Firefly Models and Creative, Marketing and Agentic Workflows
  3. [3]News articleSeeking Alpha· March 15, 2026
    Earnings week ahead: FDX, BABA, XPEV, MU, GIS, DOCU, OKLO, ACN, and more
  4. [4]News articleYahoo Finance· March 16, 2026
    NVIDIA Ignites the Next Industrial Revolution in Knowledge Work With Open Agent Development Platform

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com